← Back to patent-cliff list
Fluciclovine F 18
Tier C — Watch / tradeFluciclovine F 18
Blue Earth Diagnostics Ltd
Originator
2016
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：Not applicable
Brand：Axumin
Indications (approved)：Prostate cancer, Diagnostic agent
Regional status
US
Approved
2016-05-27
EU
Approved
2017-05-21
China
-
Japan
Approved
2021-03-23
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fluciclovine F 18?
Approved indications include: Prostate cancer, Diagnostic agent.
When does the Fluciclovine F 18 patent expire?
No public expiry year is available for Fluciclovine F 18 yet; this page updates once verified.
How do I get a quote for Fluciclovine F 18 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29